A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

References

• Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: Meta-analysis and prospective studies. J Clin Psychopharmacol 1995; 15(4 Suppl2)16S–23S
   Google Scholar
• Olsen LR, Mortensen EL, Bech P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr Scand 2004; 109: 96–103
   PubMed Web of Science ®Google Scholar
• Hildebrandt MG, Stage KB, Kragh-Soerensen P. Gender differences in severity, symptomatology and distribution of melancholia in major depression. Psychopathology 2003; 36: 204–12
   PubMedGoogle Scholar
• Stage KB, Casier P, Trosko O. [Depression]. Ugeskr Laeger 2004; 166: 1311–3
   PubMedGoogle Scholar
• Danish Medicines Agency. [Consumption of antidepressiva in Denmark in the primary health care sector during 1994–2003]. www laegemiddelstyrelsen dk 2005 [ accessed 19 January 2005].
   Google Scholar
• Danish Medicines Agency. [New rules for substitution on drugs]. http://www laegemiddelstyrelsen dk/1024/visLSArtikel asp?artikelID=5838 2005 April 1 [ accessed 1 April 2005].
   Google Scholar
• National Board of Health. Guidelines on treatment with antidepressive. Copenhagen; 2000.
   Google Scholar
• Danish College of General Practioners. [Diagnostic and treatment of depression in primary care practice], in Danish; 2001.
   Google Scholar
• Danish Society of Psychiatry & Danish College of General Practitioners. [Better treatment for patients with psychiatric diseases of non-psychotic character], in Danish; 2004.
   Google Scholar
• Stage KB. Depression management guidelines. http://www irf dk 2003 [ accessed 11 September 2004].
   Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005; 27: 111–24
   PubMed Web of Science ®Google Scholar
• Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4: 12–19
   PubMedGoogle Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911–32
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol 2004; 24: 497–506
   PubMed Web of Science ®Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: A new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004; 20: 869–78
   PubMed Web of Science ®Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004; 38: 954–60
   PubMed Web of Science ®Google Scholar
• Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004; 22: 311–9
   PubMedGoogle Scholar
• Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Manag Care Interface 2003;Suppl B:16–21.
   PubMedGoogle Scholar
• Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001; 4: 16–31
   PubMedGoogle Scholar
• Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000; 18: 143–8
   PubMed Web of Science ®Google Scholar
• Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12: 286–96
   PubMed Web of Science ®Google Scholar
• Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136–53
   PubMed Web of Science ®Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004; 19: 305–10
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Hardens M, Souetre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8: 159–68
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23: 155–67
   PubMed Web of Science ®Google Scholar
• Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997; 33: 671–6
   PubMed Web of Science ®Google Scholar
• Morrow TJ. The pharmacoeconomics of venlafaxine in depression. Am J Manag Care 2001; 7: S386–S392
   PubMedGoogle Scholar
• Sclar DA, Skaer TL, Robison LM, Galin RS. Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999; 19: 47S–54S
   Google Scholar
• François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: Comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91–107
   Google Scholar
• Lepola UM, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149–55
   PubMed Web of Science ®Google Scholar
• Drummond M, Pang F. Transferability of economic evaluation results. Economic evaluation in health care, M Drummond, A McGuire. Oxford University Press, Oxford 2001; 256–76
   Google Scholar
• Gold MR, Siegel JE, Rusell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press. 1996
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9
   PubMed Web of Science ®Google Scholar
• Korner A, Nielsen BM, Eschen F, Moller-Madsen S, Stender A, Christensen EM, et al. Quantifying depressive symptomatology: Inter-rater reliability and inter-item correlations. J Affect Disord 1990; 20: 143–9
   PubMed Web of Science ®Google Scholar
• Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: A comparative analysis. Hum Psychopharmacol 2004; 19: 9–16
   PubMedGoogle Scholar
• Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997; 9: 157–64
   PubMedGoogle Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190–6
   PubMed Web of Science ®Google Scholar
• Supplementary material available upon request: [email protected].
   Google Scholar
• Sculpher M. The role and estimation of productivity cost in economic evaluation. Economic evaluation in health care, M Drummond, A McGuire. Oxford University Press, Oxford 2001; 94–112
   Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005; 27: 486–96
   PubMed Web of Science ®Google Scholar
• Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 2004; 30: 158–66
   PubMed Web of Science ®Google Scholar
• Culpepper L. Escitalopram: A new SSRI for the treatment of depression in primary care. Prim Care Companion J Clin Psychiatry 2002; 4: 209–14
   PubMedGoogle Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131–7
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, et al. Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005; 30: 445–60
   PubMed Web of Science ®Google Scholar
• Berk M, Dodd S. Antidepressants and the placebo response. Hum Psychopharmacol 2005; 20: 305–7
   PubMed Web of Science ®Google Scholar
• Khan A, Brown WA. The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol 2001; 21: 123–5
   PubMed Web of Science ®Google Scholar
• Hansen DG, Vach W, Rosholm JU, Sondergaard J, Gram LF, Kragstrup J. Early discontinuation of antidepressants in general practice: Association with patient and prescriber characteristics. Fam Pract 2004; 21: 623–9
   PubMedGoogle Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181–8
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10(Suppl 1)29–35
   PubMedGoogle Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57–64
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De BJ, De TW, et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001; 62(Suppl 22)30–3
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001; 4: 113–8
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Switching versus augmentation: A prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001; 62: 135–42
   PubMed Web of Science ®Google Scholar
• Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001; 62(Suppl 18)12–17
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993; 5: 199–207
   PubMedGoogle Scholar
• Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24: 365–373
   PubMed Web of Science ®Google Scholar
• Bauer M, Forsthoff A, Baethge C, Adli M, Berghofer A, Dopfmer S, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2002; 253: 132–9
   Google Scholar